The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

Also called NCT01270191

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01270191
Other papers using this trial's data
  • Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia Journal of the Chinese Medical Association : JCMA, 2026-07-01 DOI, PubMed 42290292, PMC13387786 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01270191. Randomized; no masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients
Intervention (Drug)
Exenatide
Intervention (Drug)
Humulin-N
Lead sponsor
Taipei Veterans General Hospital, Taiwan (class: other government)

Record details

Record id
cardio:ct-nct01270191
Content hash
a7f1478d6330da3881b35be1bedb7774d5914c487574cb125cb68ef5b209a0e5